X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
adult (17) 17
female (17) 17
male (17) 17
middle aged (14) 14
chemotherapy (12) 12
index medicus (12) 12
hematology (11) 11
rituximab (11) 11
aged (10) 10
life sciences (10) 10
lymphoma, follicular - drug therapy (9) 9
non-hodgkins-lymphoma (9) 9
adolescent (8) 8
cyclophosphamide (8) 8
follow-up studies (8) 8
lymphoma, follicular - mortality (8) 8
oncology (8) 8
treatment outcome (8) 8
antibodies, monoclonal, murine-derived (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
bone-marrow-transplantation (7) 7
doxorubicin (7) 7
therapy (7) 7
transplantation, autologous (7) 7
immunology (6) 6
lymphoma, follicular - pathology (6) 6
lymphomas (6) 6
survival rate (6) 6
[sdv.imm]life sciences [q-bio]/immunology (5) 5
cyclophosphamide - administration & dosage (5) 5
disease-free survival (5) 5
follicular lymphoma (5) 5
hemic and lymphatic diseases (5) 5
prospective studies (5) 5
vincristine (5) 5
antibodies, monoclonal - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
bone marrow (4) 4
chop (4) 4
detude des lymphomes (4) 4
doxorubicin - administration & dosage (4) 4
doxorubicin - adverse effects (4) 4
high-dose therapy (4) 4
mesh: adult (4) 4
mesh: female (4) 4
mesh: humans (4) 4
mesh: male (4) 4
mesh: middle aged (4) 4
prednisone (4) 4
prednisone - administration & dosage (4) 4
prognosis (4) 4
progression-free survival (4) 4
remission induction (4) 4
risk factors (4) 4
stem-cell transplantation (4) 4
survival (4) 4
survival analysis (4) 4
time factors (4) 4
young adult (4) 4
[ sdv.imm ] life sciences [q-bio]/immunology (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
cancer (3) 3
care and treatment (3) 3
combined modality therapy (3) 3
cyclophosphamide - adverse effects (3) 3
disease progression (3) 3
dna, neoplasm - analysis (3) 3
doxorubicin - therapeutic use (3) 3
france (3) 3
interferon (3) 3
lymphoma, follicular (3) 3
lymphoma, follicular - therapy (3) 3
mesh: disease-free survival (3) 3
mesh: follow-up studies (3) 3
mesh: lymphoma, follicular (3) 3
mesh: survival rate (3) 3
neoplasm staging (3) 3
pathology (3) 3
positron-emission-tomography (3) 3
prednisone - adverse effects (3) 3
recurrence (3) 3
stem cell transplantation (3) 3
transplantation (3) 3
trial (3) 3
vincristine - administration & dosage (3) 3
vincristine - adverse effects (3) 3
[sdv.can]life sciences [q-bio]/cancer (2) 2
abridged index medicus (2) 2
analysis (2) 2
anti-cd20 (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal - toxicity (2) 2
antibodies, monoclonal, murine-derived - therapeutic use (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols (2) 2
biopsy (2) 2
bone marrow - pathology (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 13, pp. 1287 - 1295
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1128 - 1135
Journal Article
Human Pathology, ISSN 0046-8177, 2014, Volume 45, Issue 10, pp. 2085 - 2093
Journal Article
Haematologica, ISSN 0390-6078, 07/2013, Volume 98, Issue 7, pp. 1107 - 1114
Journal Article
by Trotman, Judith and Barrington, Sally F and Belada, David and Meignan, Michel and MacEwan, Robert and Owen, Carolyn and Ptáčník, Václav and Rosta, András and Fingerle-Rowson, Günter R and Zhu, Jiawen and Zhu, Jun and Nielsen, Tina and Sahin, Deniz and Hiddemann, Wolfgang and Marcus, Robert E and Davies, Andrew and Hertzberg, Mark and Grigg, Andrew and Cannell, Paul and Quach, Hang and Opat, Stephen and Tam, Constantine and Marlton, Paula and Janssens, Ann and Offner, Fritz and Van eygen, Koen and Sangha, Randeep and Mckay, Pam and Wilson, Jonathan and Van Der Jagt, Richard and Roitman, Daryl and Trneny, Marek and Mayer, Jiri and Le Du, Katell and Solal-Celigny, Philippe and Cartron, Guillaume and Foussard, Charles and Frickhofen, Norbert and Schmidt, Peter and Graeven, Ullrich and Gaska, Tobias and Schlag, Rudolf and Sökler, Martin and Prange-Krex, Gabriele and Florschütz, Axel and Lindemann, Hans-Walter and Schimmelpfennig, Christoph and Tonndorf, Solveig and Hänel, Mathias and Hess, Georg and Schalk, Enrico and Hütten, Heiko and Doelken, Gottfried and Pfreundschuh, Michael and Keller, Ulrich and Herold, Michael and Forstpointner, Roswitha and Vehling-Kaiser, Ursula and Hoffmann, Martin and Borbenyi, Zita and Udvardy, Miklos and Demeter, Judit and Rambaldi, Alessandro and Morra, Enrica and Massimo, Federico and Majolino, Ignazio and Balzarotti, Monica and Semenzato, Gianpietro and Canales Albendea, Miguel Angel and Peñalver Parraga, Francisco Javier and Soler Campos, Alfonso and Sancho Cia, Juan Manuel and Marquez Navarro, Jose Antonio and Grande Garcia, Carlos and Nilsson-Ehle, Herman and Mccarthy, Helen and Pocock, Chris and Sadullah, Shalal and Malladi, Ram and Radford, John and Kanfer, Ed and Kruger, Anton and Culligan, Dominic and Dyer, Martin and Pettengell, Ruth and Seymour, John and Gribben, John and Al-Ismail, Saad and Al-Refaie, Faris and Blesing, Norbert and Macnamara, Christopher and O'callaghan, Ann and Haynes, Andrew and Follows, George and Johnson, Roderick and Cunningham, David and Bowles, Kristian and Collins, Graham and Gallop-Evans, Eve and Robinson, Stephen and ... and PET investigators GALLIUM study and PET investigators from the GALLIUM study
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1530 - 1542
Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line... 
FDG-PET | CRITERIA | FONDAZIONE ITALIANA LINFOMI | SUBSET ANALYSIS | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | THERAPY | ONCOLOGY | PROGRESSION-FREE SURVIVAL | FOLL05 TRIAL | MINIMAL RESIDUAL DISEASE | Pets | Lymphomas | Prognosis | Analysis
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2812 - 2812
Introduction: Most patients with newly diagnosed FL treated with rituximab (R) alone or R + chemotherapy will experience prolonged progression-free survival... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2010, Volume 151, Issue 2, pp. 159 - 166
Summary Peripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than... 
cyclophosphamide | clinical trials | vincristine | doxorubicin | prednisone (CHOP) | T‐cell lymphoma | T-cell lymphoma | CLASSIFICATION | IFOSFAMIDE | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | PREDNISONE | THERAPY | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Ifosfamide - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Adolescent | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Anthracyclines | Cyclophosphamide | Corticosteroids | Etoposide | Clinical trials | Product development | Prednisone | Non-Hodgkin's lymphomas | T cells | double prime B-cell lymphoma | Cell survival | Vinblastine | Ifosfamide | Toxicity | Doxorubicin | Survival | Vincristine | Cisplatin | Dacarbazine | Bleomycin | Remission | double prime T-cell lymphoma | Anaplastic large-cell lymphoma | expressed sequence tags
Journal Article
Journal Article
Blood, ISSN 0006-4971, 01/2009, Volume 113, Issue 5, pp. 995 - 1001
Journal Article
Human Pathology, ISSN 0046-8177, 2008, Volume 39, Issue 2, pp. 194 - 200
Summary Rituximab, an anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphoma. Some reports have outlined histologic modifications in... 
Pathology | Anti-CD20 monoclonal antibodies | Bone marrow | Follicular lymphoma | Bcl2 | T-cell infiltration | CD20 | APOPTOSIS | follicular lymphoma | bcl2 | ANTIBODY | MECHANISMS | PATHOLOGY | bone marrow | ANTI-CD20 | anti-CD20 monoclonal antibodies | NON-HODGKIN-LYMPHOMA | EXPRESSION | Translocation, Genetic | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Lymphoma, B-Cell - genetics | Lymphoma, Follicular - genetics | Adult | Female | DNA, Neoplasm - analysis | T-Lymphocytes - pathology | Lymphoma, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived | Lymphoma, B-Cell - mortality | Lymphoma, Follicular - pathology | Lymphoma, Follicular - mortality | Rituximab | Survival Rate | Treatment Outcome | Reverse Transcriptase Polymerase Chain Reaction | Chromosomes, Human, Pair 18 | Bone Marrow - pathology | Gene Rearrangement | Lymphoma, B-Cell - pathology | Chromosomes, Human, Pair 14 | Aged | Proto-Oncogene Proteins c-bcl-2 - genetics | Antimitotic agents | Care and treatment | Lymphomas | T cells | Antineoplastic agents | Health aspects | Cancer | Histology | Genes | Binding sites | T-Lymphocytes | Antineoplastic Agents | Antibodies, Monoclonal | Lymphoma, B-Cell | Life Sciences | Human health and pathology | DNA, Neoplasm | Lymphoma, Follicular | Proto-Oncogene Proteins c-bcl-2 | Bone Marrow
Journal Article